[1] |
LI X, CHENG J, ZHOU Z G. Revisiting multiple models of progression of β-cell loss of function in type 1 diabetes: significance for prevention and cure[J]. J Diabetes, 2016, 8: 460-469. DOI:10.1111/1753-0407.12376 |
[2] |
SILVA M J, BRODT M D, LYNCH M A, MCKENZIE J A, TANOUYE K M, NYMAN J S, et al. Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life[J]. J Bone Miner Res, 2009, 24: 1618-1627. DOI:10.1359/jbmr.090316 |
[3] |
LÉGER J, MARINOVIC D, ALBERTI C, DORGERET S, CHEVENNE D, MARCHAL C L, et al. Lower bone mineral content in children with type 1 diabetes mellitus is linked to female sex, low insulin-like growth factor type Ⅰ levels, and high insulin requirement[J]. J Clin Endocrinol Metab, 2006, 91: 3947-3953. DOI:10.1210/jc.2006-0711 |
[4] |
THRAILKILL K M, LUMPKIN C K Jr, BUNN R C, KEMP S F, FOWLKES J L. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues[J/OL]. Am J Physiol Endocrinol Metab, 2005, 289: E735-E745. DOI: 10.1152/ajpendo.00159.2005.
|
[5] |
VOGT M T, CAULEY J A, KULLER L H, NEVITT M C. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures[J]. J Bone Miner Res, 1997, 12: 283-289. DOI:10.1359/jbmr.1997.12.2.283 |
[6] |
JACOBSEN I B, HENRIKSEN J E, BECK-NIELSEN H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control[J]. Basic Clin Pharmacol Toxicol, 2009, 105: 145-149. DOI:10.1111/j.1742-7843.2009.00380.x |
[7] |
LIBMAN I M, MILLER K M, DIMEGLIO L A, BETHIN K E, KATZ M L, SHAH A, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial[J]. JAMA, 2015, 314: 2241-2250. DOI:10.1001/jama.2015.16174 |
[8] |
K A N A Z AWA I, YA M A G U C H I T, YA N O S, YAMAUCHI M, YAMAMOTO M, SUGIMOTO T. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells[J/OL]. BMC Cell Biol, 2007, 8: 51. DOI: 10.1186/1471-2121-8-51.
|
[9] |
TAKENO A, KANAZAWA I, TANAKA K I, NOTSU M, YOKOMOTO M, YAMAGUCHI T, et al. Activation of AMP-activated protein kinase protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2[J]. Bone, 2015, 77: 135-141. DOI:10.1016/j.bone.2015.04.025 |
[10] |
LIU L S, ZHANG C, HU Y J, PENG B. Protective effect of metformin on periapical lesions in rats by decreasing the ratio of receptor activator of nuclear factor κB ligand/osteoprotegerin[J]. J Endod, 2012, 38: 943-947. DOI:10.1016/j.joen.2012.03.010 |
[11] |
SCHURMAN L, MCCARTHY A D, SEDLINSKY C, GANGOITI M V, ARNOL V, BRUZZONE L, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells[J]. Exp Clin Endocrinol Diabetes, 2008, 116: 333-340. DOI:10.1055/s-2007-992786 |
[12] |
LI X Y, GUO Y Q, YAN W B, SNYDER M P, LI X. Metformin improves diabetic bone health by rebalancing catabolism and nitrogen disposal[J/OL]. PLoS One, 2015, 10: e0146152. DOI: 10.1371/journal.pone.0146152.
|
[13] |
GUO Y Q, XIE C Z, LI X Y, YANG J, YU T, ZHANG R H, et al. Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis[J/OL]. Nat Commun, 2017, 8: 15621. DOI: 10.1038/ncomms15621.
|
[14] |
American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care, 2013, 36(Suppl 1): S67-S74. |
[15] |
PAN H, WU N P, YANG T, HE W. Association between bone mineral density and type 1 diabetes mellitus: a meta-analysis of cross-sectional studies[J]. Diabetes Metab Res Rev, 2014, 30: 531-542. DOI:10.1002/dmrr.2508 |
[16] |
CHIANG J L, KIRKMAN M S, LAFFEL L M B, PETERS A L; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association[J]. Diabetes Care, 2014, 37: 2034-2054. DOI:10.2337/dc14-1140 |
[17] |
BOTOLIN S, MCCABE L R. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways[J]. J Cell Biochem, 2006, 99: 411-424. DOI:10.1002/jcb.20842 |
[18] |
LECHLEITNER M, KOCH T, HEROLD M, DZIEN A, HOPPICHLER F. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors[J]. J Intern Med, 2000, 248: 67-76. DOI:10.1046/j.1365-2796.2000.00705.x |
[19] |
NOJIRI H, SAITA Y, MORIKAWA D, KOBAYASHI K, TSUDA C, MIYAZAKI T, et al. Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking[J]. J Bone Miner Res, 2011, 26: 2682-2694. DOI:10.1002/jbmr.489 |
[20] |
MOTYL K J, BOTOLIN S, IRWIN R, APPLEDORN D M, KADAKIA T, AMALFITANO A, et al. Bone inflammation and altered gene expression with type Ⅰ diabetes early onset[J]. J Cell Physiol, 2009, 218: 575-583. DOI:10.1002/jcp.21626 |
[21] |
SAITO M, MARUMO K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus[J]. Osteoporos Int, 2010, 21: 195-214. DOI:10.1007/s00198-009-1066-z |
[22] |
MCCABE L R. Understanding the pathology and mechanisms of type Ⅰ diabetic bone loss[J]. J Cell Biochem, 2007, 102: 1343-1357. DOI:10.1002/jcb.21573 |
[23] |
SIDDAPPA R, MULDER W, STEEGHS I, VAN DE KLUNDERT C, FERNANDES H, LIU J, et al. cAMP/ PKA signaling inhibits osteogenic differentiation and bone formation in rodent models[J]. Tissue Eng Part A, 2009, 15: 2135-2143. DOI:10.1089/ten.tea.2008.0512 |
[24] |
TANKOVA T. Current indications for metformin therapy[J]. Rom J Intern Med, 2003, 41: 215-225. |
[25] |
KUME S, KATO S, YAMAGISHI S I, INAGAKI Y, UEDA S, ARIMA N, et al. Advanced glycation endproducts attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone[J]. J Bone Miner Res, 2005, 20: 1647-1658. DOI:10.1359/JBMR.050514 |
[26] |
MA J, ZHANG Z L, HU X T, WANG X T, CHEN A M. Metformin promotes differentiation of human bone marrow derived mesenchymal stem cells into osteoblast via GSK3β inhibition[J]. Eur Rev Med Pharmacol Sci, 2018, 22: 7962-7968. |
[27] |
ZHENG L F, SHEN X M, YE J J, XIE Y, YAN S J. Metformin alleviates hyperglycemia-induced apoptosis and differentiation suppression in osteoblasts through inhibiting the TLR4 signaling pathway[J]. Life Sci, 2019, 216: 29-38. DOI:10.1016/j.lfs.2018.11.008 |
[28] |
MU W, WANG Z R, MA C Y, JIANG Y Y, ZHANG N N, HU K Q, et al. Metformin promotes the proliferation and differentiation of murine preosteoblast by regulating the expression of sirt6 and oct4[J]. Pharmacol Res, 2018, 129: 462-474. DOI:10.1016/j.phrs.2017.11.020 |
[29] |
WANG L X, WANG G Y, SU N, MA J, LI Y K. Effects of different doses of metformin on bone mineral density and bone metabolism in elderly male patients with type 2 diabetes mellitus[J]. World J Clin Cases, 2020, 8: 4010-4016. DOI:10.12998/wjcc.v8.i18.4010 |
[30] |
WU W, YE Z Y, ZHOU Y, TAN W S. AICAR, a small chemical molecule, primes osteogenic differentiation of adult mesenchymal stem cells[J]. Int J Artif Organs, 2011, 34: 1128-1136. DOI:10.5301/ijao.5000007 |